1-(4-fluorophenyl)-N-(4-((7-((7-(hydroxyamino)-7-oxoheptyl)oxy)-6-methoxyquinolin-4-yl)oxy)phenyl)-2-oxopyrrolidine-3-carboxamide

ID: ALA5269169

Chembl Id: CHEMBL5269169

Max Phase: Preclinical

Molecular Formula: C34H35FN4O7

Molecular Weight: 630.67

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cc2c(Oc3ccc(NC(=O)C4CCN(c5ccc(F)cc5)C4=O)cc3)ccnc2cc1OCCCCCCC(=O)NO

Standard InChI:  InChI=1S/C34H35FN4O7/c1-44-30-20-27-28(21-31(30)45-19-5-3-2-4-6-32(40)38-43)36-17-15-29(27)46-25-13-9-23(10-14-25)37-33(41)26-16-18-39(34(26)42)24-11-7-22(35)8-12-24/h7-15,17,20-21,26,43H,2-6,16,18-19H2,1H3,(H,37,41)(H,38,40)

Standard InChI Key:  BLMPKINHBQAHPE-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5269169

    ---

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCT-116 (91556 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 630.67Molecular Weight (Monoisotopic): 630.2490AlogP: 6.00#Rotatable Bonds: 14
Polar Surface Area: 139.32Molecular Species: NEUTRALHBA: 8HBD: 3
#RO5 Violations: 2HBA (Lipinski): 11HBD (Lipinski): 3#RO5 Violations (Lipinski): 3
CX Acidic pKa: 8.91CX Basic pKa: 5.88CX LogP: 4.48CX LogD: 4.46
Aromatic Rings: 4Heavy Atoms: 46QED Weighted: 0.07Np Likeness Score: -1.03

References

1. Lauria A, La Monica G, Bono A, Martorana A..  (2021)  Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.,  220  [PMID:34052677] [10.1016/j.ejmech.2021.113555]

Source